9 completed, 2 recruiting, 2 terminated, 1 not yet recruiting. 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 9, Recruiting 2, Terminated 2, Not yet recruiting 1 |
Follow valbenazine: new trials by email Literature Review of valbenazine trials Research Report on valbenazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valbenazine in Obsessive Compulsive Disorder Valbenazine, Placebo - Obsessive-Compulsive Disorder | Phase 2 | Not yet recruiting | University of Chicago | 30 | 2026-06-01 | 2026-06-10 |
| Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia Valbenazine, Placebo - Cervical Dystonia | Phase 2 | Recruiting | Virginia Commonwealth University | 20 | 2024-12-17 | 2026-06-04 |
| Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults Valbenazine Oral Capsule, Placebo Oral capsule - Trichotillomania (Hair-Pulling Disorder) | Phase 2 | Recruiting | Yale University | 20 | 2024-02-02 | 2026-02-03 |
| Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome NBI-98854 - Tourette Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 6 | 2018-10-17 | 2022-04-19 |
| Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Valbenazine, Placebo oral capsule - Tourette Syndrome | Phase 2 | Terminated | Neurocrine Biosciences | 81 | 2018-04-17 | 2022-05-17 |
| Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Valbenazine - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 85 | 2018-02-08 | 2022-02-23 |
| Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Valbenazine, Placebo oral capsule - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 127 | 2017-10-05 | 2021-06-28 |
| Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Valbenazine - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 155 | 2016-07-25 | 2021-04-29 |
| Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome NBI-98854, Placebo - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 98 | 2016-03-23 | 2021-01-15 |
| Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome NBI-98854, Placebo - Tourette Syndrome | Phase 2 | Completed | Neurocrine Biosciences | 124 | 2015-11-01 | 2020-05-07 |
| NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia NBI-98854, Placebo - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 102 | 2012-12-01 | 2017-08-10 |
| NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) NBI-98854, Placebo - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 109 | 2012-09-01 | 2017-11-08 |
| NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder NBI-98854, Placebo - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 37 | 2011-08-01 | 2017-08-10 |
| Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia NBI-98854 - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 10 | 2011-01-01 | 2011-04-20 |
Tourette Syndrome (7) · Tardive Dyskinesia (4) · Obsessive-Compulsive Disorder (1) · Torticollis (1) · Trichotillomania (1)
Neurocrine Biosciences (11) · University of Chicago (1) · Virginia Commonwealth University (1) · Yale University (1)
United States (12) · Puerto Rico (6) · Canada (1)
Chris O'Brien, MD (2) · Brian Berman (1) · Christopher O'Brien, MD (1) · Jon E Grant, MD, JD, MPH (1) · Michael H. Bloch, MD (1)